Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has entered into a further contract with its existing client Cancer Research UK.
Physiomics was first retained in July 2019 by Bicycle Therapeutics and Cancer Research UK to conduct Pharmacokinetics (PK), analyses (what the body does to the drug) of clinical data arising from the Cancer Research UK-sponsored Phase I/IIa clinical trial in solid tumours with the Bicycle Therapeutics’ program, BT1718.
The follow-on project announced today will be contracted directly with Cancer Research UK and represents the second such directly contracted project following the award completion last month of a contract for PKPD (pharmacodynamics, what the drug does to the body) modelling relating to the Cancer Research UK-sponsored clinical trial of ALETA-001, a CAR-T cell engager candidate for the treatment of blood cancers developed by Aleta Biotherapeutics.
The project is expected to be completed during Q1 2023.
Dr Jim Millen, CEO of Physiomics, commented:
“We are very pleased to be working on this second project with Cancer Research UK, the UK’s leading cancer research charity and look forward to developing our relationship further going forwards.”
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.